2m 2m 2m 2m 2m 2m 2m
- $13.8BMarket Cap
- 6.19%1-Year Change
- Medical Care FacilitiesIndustry
Fresenius Sp.ADR (FMS)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 86
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
A new analysis by Spherix Global Insights reveals that access barriers, not efficacy issues, are limiting Xphozah (tenapanor) uptake in the dialysis hyperphosphatemia market. Nephrologists report they would nearly triple Xphozah use without reimbursement and coverage obstacles. However, the drug faces persistence challenges with gastrointestinal tolerability causing discontinuation rates to double to 8%. The findings also show physicians significantly overestimate phosphorus control and combination therapy use among patients. As the TDAPA reimbursement program expires at the end of 2026, phosphate-lowering therapies will face a flattened competitive landscape.
07/29/2026, 10:46 AM • GlobeNewswire
Urology Devices Market Size to Reach USD 80.0 Billion by 2035 | SNS Insider
The global urology devices market is valued at USD 39.23 billion in 2025 and is projected to reach USD 80.0 billion by 2035, growing at a CAGR of 7.35%. Growth is driven by rising demand for robotic-assisted surgery, kidney disease treatment, and minimally invasive procedures. North America leads the market while Asia Pacific records the fastest growth.
07/20/2026, 7:53 AM • GlobeNewswire
The U.S. arteriovenous fistula devices market is projected to grow from $112 million in 2025 to $120 million by 2033, driven by rising end-stage renal disease cases and increasing demand for advanced vascular access solutions.
11/19/2025, 4:57 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 07/31/2026
Company Profile
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Key Executives
- Helen Giza
- Craig Cordola FACHE
- Joseph E. Turk Jr.
- Charles Hugh-Jones
- Martin Fischer
Current Ownership Distribution
- Institutions644.3M (73.42%)
- Mutual Funds233.2M (26.58%)
- Insiders0 (0.00%)
- Other0 (0.00%)